Plasma Aβ₄₂:Aβ₄₀ ratio as a biomarker for cognitive impairment in haemodialysis patients: a multicentre study.

ABSTRACT:

Background

Mild cognitive impairment (MCI) and dementia are more prevalent in patients undergoing haemodialysis (HD). Although the cerebrospinal fluid amyloid beta (Aβ) and tau (τ) have proven to be valid biomarkers for the diagnosis of Alzheimer's disease (AD) in the general population, the roles of plasma Aβ and τ for the diagnosis of cognitive impairment in HD patients remain unknown.

Methods

We conducted a cross-sectional study including patients receiving HD in three hospitals in Shanghai. All patients completed the Montreal Cognitive Assessment-Basic (MoCA-B). To validate the effectiveness of the MoCA-B score for screening MCI, a subset group underwent neuropsychological batteries. Serum proteomes were compared in HD patients with normal cognitive function and dementia

SUBMITTER: Chen X 

PROVIDER: S-EPMC10616443 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature